Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Despite the improvement of surgical resection as primary curative treatment for gastric
cancer, more than 70% of patients with stage IIIB and IV disease undergoing radical primary
tumor resection relapse and die within 5 years. Therefore, there is an urgent need to further
improve the treatment for gastric cancer in this population. Recently reported phase III
study comparing capecitabine/cisplatin (XP) versus 5-FU/cisplatin (FP), XP showed better
activity and tolerability compared with FP. To improve treatment outcomes of XP chemotherapy,
the investigators performed a phase I-II study of docetaxel, capecitabine and cisplatin in
advanced gastric cancer (AGC). Phase I-II study of docetaxel, capecitabine and cisplatin as
first-line chemotherapy in advanced gastric cancer (Kang et al, Proc Am Soc Clin Oncol
22,328.2003). The docetaxel/capecitabine/cisplatin (DXP) chemotherapy was highly active for
the 1st-line chemotherapy of AGC. These findings and experience encourages the investigators
to design the adjuvant trial of DXP chemotherapy in patients with resected gastric cancer.
The aim of this study is to assess the efficacy and safety of adjuvant DXP in this patient
population.